Cabell K S, Ma L, Johnson P
Department of Chemistry and College of Osteopathic Medicine, Ohio University, Athens 45701, U.S.A.
Biochem Pharmacol. 1997 Jul 1;54(1):133-41. doi: 10.1016/s0006-2952(97)00161-5.
The effects of three commonly used antihypertensive agents (captopril, hydralazine, and terazosin) on tissue antioxidant enzymes and lipid peroxidation in spontaneously hypertensive (SHR) and normotensive Wistar-Kyoto (WKY rats) were studied by analysis of antioxidant enzyme specific activities and lipid peroxidation levels in control and drug-treated animals. In the myocardium, changes in some of the enzyme activities between normotensive WKY and hypertensive SHR rats were mitigated by treatment of the SHR rats with an antihypertensive drug. Thus, all three drugs caused significant increases in myocardial Cu/Zn superoxide dismutase (up to 133% of SHR control activity) and decreases in glutathione peroxidase (down to 59% of SHR control activity) to values that were closer to those in untreated WKY rats. Captopril also increased Mn superoxide dismutase activity, and hydralazine and terazosin decreased catalase activity towards untreated WKY values. Hydralazine was the only drug to alter the lipid peroxidation level in the myocardium of SHR rats (a 28% decrease), but in WKY rats all three drugs caused significant decreases in myocardial lipid peroxidation levels. In WKY rats, none of the drugs affected myocardial Mn and Cu/Zn superoxide dismutase activities, although glutathione peroxidase activity was decreased by hydralazine and terazosin treatment and catalase activity was increased by captopril treatment. Enzyme activity changes in liver and skeletal muscle indicated that such changes were often tissue specific. No pattern was found for coordinated changes in antioxidant enzyme expression as a result of the drug treatments, and the changes in antioxidant enzyme specific activities did not correlate generally with changes in lipid peroxidation levels.
通过分析对照动物和药物处理动物的抗氧化酶比活性及脂质过氧化水平,研究了三种常用抗高血压药物(卡托普利、肼屈嗪和特拉唑嗪)对自发性高血压大鼠(SHR)和正常血压的Wistar - Kyoto大鼠(WKY大鼠)组织抗氧化酶和脂质过氧化的影响。在心肌中,正常血压的WKY大鼠和高血压的SHR大鼠之间某些酶活性的变化,通过用抗高血压药物治疗SHR大鼠而得到缓解。因此,所有三种药物均使心肌铜/锌超氧化物歧化酶显著增加(高达SHR对照活性的133%),并使谷胱甘肽过氧化物酶降低(降至SHR对照活性的59%),达到更接近未治疗WKY大鼠的值。卡托普利还增加了锰超氧化物歧化酶活性,肼屈嗪和特拉唑嗪使过氧化氢酶活性降至未治疗WKY大鼠的值。肼屈嗪是唯一改变SHR大鼠心肌脂质过氧化水平的药物(降低28%),但在WKY大鼠中,所有三种药物均使心肌脂质过氧化水平显著降低。在WKY大鼠中,尽管肼屈嗪和特拉唑嗪治疗降低了谷胱甘肽过氧化物酶活性,卡托普利治疗增加了过氧化氢酶活性,但没有一种药物影响心肌锰和铜/锌超氧化物歧化酶活性。肝脏和骨骼肌中的酶活性变化表明,这些变化通常具有组织特异性。未发现药物治疗导致抗氧化酶表达协同变化的模式,抗氧化酶比活性的变化一般与脂质过氧化水平的变化无关。